Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:2642-2649
doi: 10.1161/CIRCULATIONAHA.105.540500
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borlaug, B. A.
Right arrow Articles by Kass, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borlaug, B. A.
Right arrow Articles by Kass, D. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Contractile function
Right arrow Cardiovascular Pharmacology
Right arrowRelated Article

(Circulation. 2005;112:2642-2649.)
© 2005 American Heart Association, Inc.


Heart Failure

Sildenafil Inhibits ß-Adrenergic–Stimulated Cardiac Contractility in Humans

Barry A. Borlaug, MD; Vojtech Melenovsky, MD, PhD; Tricia Marhin, RN, BSN; Patricia Fitzgerald, RN, BSN; David A. Kass, MD

From the Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Md.

Correspondence to David A. Kass, MD, Abraham and Virginia Weiss Professor of Cardiology, Johns Hopkins Medical Institutions, Ross 835, 720 Rutland Ave, Baltimore, MD 21205. E-mail dkass{at}jhmi.edu

Received February 5, 2005; revision received May 18, 2005; accepted July 8, 2005.

Background— Sildenafil inhibits phosphodiesterase 5 (PDE5A) to elevate intracellular cGMP and to induce vasodilation. This effect has led to its use for treating erectile dysfunction. Although its influence on rest heart function has appeared minimal, recent animal studies suggest that sildenafil can have potent effects on hearts stimulated by ß-adrenergic or pressure overloads. We therefore tested whether sildenafil blunts dobutamine-stimulated cardiac function in humans.

Methods and Results— Thirty-five healthy volunteers underwent a randomized, double-blind, placebo-controlled study in which cardiac function was assessed in response to dobutamine before and after oral sildenafil (100 mg, n=19) or placebo (n=16). Echo Doppler and noninvasive blood pressure data yielded load-independent contractility indexes (maximal power index and end-systolic elastance), ejection fraction, and measures of diastolic function. In the initial dobutamine test, systolic and diastolic function improved similarly in both treatment groups (eg, peak power index rose 80±28% in the placebo group and 82±31% in the sildenafil group; P=NS). However, in subjects who then received sildenafil, their second dobutamine response was significantly blunted, with peak power, ejection fraction, and end-systolic elastance changes reduced by 32±34%, 66±64%, and 56±63%, respectively (each P<0.001 versus the initial response). This contrasted to the placebo group, which displayed similar functional responses with both dobutamine tests. Sildenafil treatment did not significantly alter diastolic changes induced by dobutamine compared with results with placebo.

Conclusions— PDE5A inhibition by sildenafil blunts systolic responses to ß-adrenergic stimulation. This finding supports activity of PDE5A in the human heart and its role in modifying stimulated cardiac function.


Key Words: contractility • pharmacology • phosphodiesterase 5 • receptors, adrenergic, beta • sildenafil


Related Article:

Issue Highlights
Circulation 2005 112: 2581. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Circ. Res.Home page
E. Takimoto
Controlling Myocyte cGMP: Phosphodiesterase 1 Joins the Fray
Circ. Res., November 6, 2009; 105(10): 931 - 933.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Melenovsky, H. Al-Hiti, L. Kazdova, A. Jabor, P. Syrovatka, I. Malek, J. Kettner, and J. Kautzner
Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil.
J. Am. Coll. Cardiol., August 11, 2009; 54(7): 595 - 600.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Reffelmann and R. A. Kloner
Phosphodiesterase 5 inhibitors: are they cardioprotective?
Cardiovasc Res, July 15, 2009; 83(2): 204 - 212.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. S.P. Lam, V. L. Roger, R. J. Rodeheffer, B. A. Borlaug, F. T. Enders, and M. M. Redfield
Pulmonary hypertension in heart failure with preserved ejection fraction a community-based study.
J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1119 - 1126.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Pokreisz, S. Vandenwijngaert, V. Bito, A. Van den Bergh, I. Lenaerts, C. Busch, G. Marsboom, O. Gheysens, P. Vermeersch, L. Biesmans, et al.
Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice
Circulation, January 27, 2009; 119(3): 408 - 416.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K. L. Gabrielson, E. Takimoto, and D. A. Kass
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.
J. Am. Coll. Cardiol., January 13, 2009; 53(2): 207 - 215.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
M. Guazzi
Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure
Circ Heart Fail, November 1, 2008; 1(4): 272 - 280.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Nagayama, M. Zhang, S. Hsu, E. Takimoto, and D. A. Kass
Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 380 - 387.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Guazzi, M. Samaja, R. Arena, M. Vicenzi, and M. D. Guazzi
Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure
J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2136 - 2144.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Goldsmith
Type 5 Phosphodiesterase Inhibition in Heart Failure: The Next Step
J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2145 - 2147.
[Full Text] [PDF]


Home page
Circ. Res.Home page
D. A. Kass, H. C. Champion, and J. A. Beavo
Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation
Circ. Res., November 26, 2007; 101(11): 1084 - 1095.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. A. Borlaug, V. Melenovsky, M. M. Redfield, K. Kessler, H.-J. Chang, T. P. Abraham, and D. A. Kass
Impact of Arterial Load and Loading Sequence on Left Ventricular Tissue Velocities in Humans
J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1570 - 1577.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. A. Kass
Hypertrophied Right Hearts Get Two for the Price of One: Can Inhibiting Phosphodiesterase Type 5 Also Inhibit Phosphodiesterase Type 3?
Circulation, July 17, 2007; 116(3): 233 - 235.
[Full Text] [PDF]


Home page
CirculationHome page
J. Nagendran, S. L. Archer, D. Soliman, V. Gurtu, R. Moudgil, A. Haromy, C. St. Aubin, L. Webster, I. M. Rebeyka, D. B. Ross, et al.
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility
Circulation, July 17, 2007; 116(3): 238 - 248.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. A. Kass, E. Takimoto, T. Nagayama, and H. C. Champion
Phosphodiesterase regulation of nitric oxide signaling
Cardiovasc Res, July 15, 2007; 75(2): 303 - 314.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. T.-J. Gan, S. Holverda, J. T. Marcus, W. J. Paulus, K. M. Marques, J. G.F. Bronzwaer, J. W. Twisk, A. Boonstra, P. E. Postmus, and A. Vonk-Noordegraaf
Right Ventricular Diastolic Dysfunction and the Acute Effects of Sildenafil in Pulmonary Hypertension Patients
Chest, July 1, 2007; 132(1): 11 - 17.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Jabbour, A. Keogh, C. Hayward, and P. Macdonald
Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation
Eur J Heart Fail, June 1, 2007; 9(6-7): 674 - 677.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. Takimoto, D. Belardi, C. G. Tocchetti, S. Vahebi, G. Cormaci, E. A. Ketner, A. L. Moens, H. C. Champion, and D. A. Kass
Compartmentalization of Cardiac {beta}-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5
Circulation, April 24, 2007; 115(16): 2159 - 2167.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. A. Borlaug, V. Melenovsky, S. D. Russell, K. Kessler, K. Pacak, L. C. Becker, and D. A. Kass
Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction
Circulation, November 14, 2006; 114(20): 2138 - 2147.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele
Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases
Circ. Res., October 13, 2006; 99(8): 816 - 828.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. R.V. Castro, I. Verde, D. M.F. Cooper, and R. Fischmeister
Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes
Circulation, May 9, 2006; 113(18): 2221 - 2228.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. J. Semigran
Type 5 Phosphodiesterase Inhibition: The Focus Shifts to the Heart
Circulation, October 25, 2005; 112(17): 2589 - 2591.
[Full Text] [PDF]